国海证券研报指出，亚宝药业丁桂儿脐贴围绕"外用治腹泻"的产品定位，持续加强品牌宣传，同时实 施"重点43城进攻战"，巩固优势市场，拓展潜力市场。根据IQVIA2024年数据显示，丁桂儿脐贴在地级 市市场份额达19%，同比提升3个百分点，持续领跑儿童止泻外用品类市场。同时公司积极培育儿科新 品，通过实施"丁桂金种子计划"，"丁桂"系列儿科新品2024年累计实现覆盖终端1.2万余家，覆盖中小 型连锁890余家。布局创新药与中药新药研发。公司多个创新药项目取得新进展，SY-005治疗脓毒症适 应症目前处于Ⅱ期临床阶段，2025年8月SY-005项目新适应症脑胶质瘤术后神经功能缺损获批临床试 验。看好公司在儿科药领域的品牌优势和产品储备，同时看好公司创新药布局带来的潜在第二增长曲 线，首次覆盖，给予"增持"评级。 ...

2025 年 09 月 10 日 晨会纪要 研究所： 证券分析师： 余春生 S0350513090001 yucs@ghzq.com.cn 观点精粹: 最新报告摘要 海外映射视角下的 AI 应用投资机会--策略 PPT Q2 业绩稳健，收购桥沟矿业 50%股权--兴发集团/农化制品(600141/212208) 公司动态研究 稳步推进混合所有制改革，公司未来增长动能强劲--通用股份/汽车零部件(601500/212802) 公司动态研究 复合肥量利齐升，磷肥出口带来增量--史丹利/农化制品(002588/212208) 公司动态研究 医保和集采政策影响趋于平稳，业绩筑底下半年增速有望改善--新里程/医疗服务(002219/213706) 公司动态 研究 Q2 业绩环比修复，新建项目持续提供发展动能--华鲁恒升/农化制品(600426/212208) 公司动态研究 业绩符合预告指引，关注《奔奔王国》上线表现--ST 华通/游戏Ⅱ(002602/217204) 公司专题研究（无评级） 中药配方颗粒短期承压，血必净注射液稳健增长--红日药业/中药Ⅱ(300026/213702) 公司动态研究 Q2 业绩稳中有增，磷 ...

Core Viewpoint - The report highlights a significant decline in revenue and net profit for Yabao Pharmaceutical Group in the first half of 2025, primarily due to decreased sales in key products and the overall impact of market conditions on the pharmaceutical industry [2][7]. Company Overview and Financial Indicators - Yabao Pharmaceutical Group's revenue for the first half of 2025 was approximately 1.14 billion RMB, a decrease of 21.08% compared to the same period last year [2][7]. - The total profit for the period was approximately 212.43 million RMB, showing a slight decrease of 0.18% year-on-year [2][7]. - The net profit attributable to shareholders was approximately 174.40 million RMB, down 2.99% from the previous year [2][7]. - The company's total assets decreased by 2.55% to approximately 3.45 billion RMB, while net assets attributable to shareholders decreased by 3.22% to approximately 2.80 billion RMB [2][7]. Industry Development - The pharmaceutical manufacturing industry in China saw a slight decline in revenue of 1.2% and a profit decrease of 2.8% in the first half of 2025, reflecting broader market challenges [7][8]. - The government has emphasized the importance of traditional Chinese medicine (TCM) and has implemented policies to support its development, which is expected to enhance the demand for TCM products [7][8]. Main Business Operations - Yabao Pharmaceutical focuses on the research, production, and sales of pharmaceutical products, with over 300 varieties including tablets, injections, and special medical foods [7][8]. - The company has a strong emphasis on pediatric medicine, with a strategic goal of being a leader in this field, and has developed a range of products specifically for children [7][8]. Sales and Marketing Strategy - The company has established a comprehensive marketing network covering 32 provinces and cities in China, collaborating with approximately 5,400 large pharmaceutical distributors [7][8]. - Yabao Pharmaceutical has implemented various sales models tailored to different product types and market segments, enhancing its market presence and customer reach [7][8]. Research and Development - The company is actively engaged in the development of innovative drugs, generic drugs, and improved formulations, with a focus on pediatric and traditional Chinese medicine [7][8]. - Yabao Pharmaceutical has established partnerships with various research institutions and has invested in advanced technologies to enhance its R&D capabilities [7][8].

Core Viewpoint - The company has developed a comprehensive range of children's and infant products under the Dinggui® brand, focusing on various pediatric needs [2]. Product Range - The company offers a total of 36 products, including Dinggui children's navel patches, children's throat relief oral liquid, Yiyang Jianpi gel, zinc gluconate oral liquid, and anti-swelling and pain relief patches [2]. - The product line addresses multiple pediatric areas such as digestion, respiratory health, nutritional support, anti-infection, and anti-allergy [2].

Core Viewpoint - The article highlights the development of the "Harmonious Automotive and Material" (合汽生材) industry strategy in Yuncheng, focusing on the integration of traditional industries with emerging sectors, particularly in smart manufacturing, new materials, and biomedicine [2][4][8]. Group 1: Industry Development Strategy - Yuncheng has proposed the "Harmonious Automotive and Material" strategy to enhance its industrial structure, emphasizing the integration of industrialization and informatization, smart connected vehicles, biomedicine, and advanced materials [2][3][4]. - The strategy aims to create a modern industrial system with Yuncheng characteristics, leveraging its industrial foundation and national strategic alignment [2][3]. Group 2: Policy Implementation - A series of supportive policies have been established, including the creation of an industry fund, tax service measures, and talent recruitment initiatives to facilitate the implementation of the "Harmonious Automotive and Material" strategy [3][4]. - Yuncheng has focused on attracting quality industrial projects through investment promotion and optimizing the business environment, resulting in significant project signings [3][8]. Group 3: Emerging Industry Clusters - The "Harmonious Automotive and Material" strategy has led to the formation of significant industry clusters in Yuncheng, particularly in smart manufacturing and new materials, with companies like Yuncheng Jianlong and Aoxin Technology leading the way [5][6][7]. - The new materials sector has become a crucial part of Yuncheng's strategic emerging industries, accounting for 25% of the total, with advancements in lithium battery separators and other high-tech materials [7][8]. Group 4: Economic Impact and Growth - In 2024, the added value of the strategic emerging industries in Yuncheng accounted for 24.6% of the total industrial output, with the "Harmonious Automotive and Material" sector contributing 73.8% of that value [8]. - The city has signed 226 projects with a total investment of 1,082.2 billion, with 72.7% being strategic emerging industry projects, indicating robust economic growth and development [8].